ImaginAb has signed a multiyear licensing agreement with Genmab to supply the company with its investigational zirconium-89 (Zr-89)-based PET radiopharmaceutical for use in clinical trials.
Zr-89 crefmirlimab berdoxam is an immuno-PET tracer that binds the CD8 receptor on human T cells and is used for quantitative PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies.
The radiotracer eventually may be used in quantitative imaging of CD8 T cells to determine the immune status of patients and measure the efficacy of immunotherapies, the company said.
